Skip to main content
Premium Trial:

Request an Annual Quote

Cellzome, Graffinity Win $2.6M from German Gov t to Develop Immune System Treatments

NEW YORK, Oct. 12 (GenomeWeb News) - Cellzome and Graffinity, a unit of Santhera Pharmaceuticals, will receive €1.1 million ($1.3 million) each from the German Ministry of Research and Education to discover new treatments for immune system disorders, the Heidelberg, Germany-based companies said today.

 

Over the next two years, Graffinity will screen up to nine targets provided by Cellzome,

using its fragment-based screening platform. It will also use part of the funding to increase the sensitivity of its technology.Cellzome will make use of its proteomics platform to identify targets and to profile hits and leads resulting from the collaboration.

 

The aim of the project is to discover small molecule leads directed against several kinases in signalling pathways of the immune system.